Advertisement

Differential Effect of Telmisartan and Amlodipine on Monocyte Chemoattractant Protein-1 and Peroxisome Proliferator-Activated Receptor-Gamma Gene Expression in Peripheral Monocytes in Patients With Essential Hypertension

      Monocyte chemoattractant protein-1 (MCP-1) and peroxisome proliferator-activated receptor-γ (PPAR-γ) play a significant role in monocyte activation, vascular inflammation, and atherogenesis. Angiotensin receptor blockers and calcium channel blockers are antihypertensive drugs with established efficacy and a favorable safety profile. We investigated the effect of telmisartan—an angiotensin receptor blocker with PPAR-γ agonist activity—and amlodipine on the activation state of peripheral blood monocytes with respect to MCP-1 and PPAR-γ gene expression in hypertensives. We recruited 31 previously untreated patients with essential hypertension who were randomly assigned to receive treatment with telmisartan (n = 16) or amlodipine (n = 15). Blood samples were taken before and 3 months after therapy initiation. Mononuclear cells were isolated and mRNAs of MCP-1 and PPAR-γ were estimated by real-time quantitative reverse transcription–polymerase chain reaction each time. The 2 treatments decreased all blood pressure components significantly (p <0.001). In contrast, in the amlodipine group, MCP-1 gene expression was significantly downregulated after treatment with telmisartan (from 21.4 ± 20.5 to 8.1 ± 6.5, p = 0.009), whereas the amlodipine group did not show any significant change (12.5 ± 8.5 vs 17.6 ± 16.4, p = NS). In addition, PPAR-γ mRNA levels showed a significant increase in telmisartan-treated patients (from 20 ± 18.5 to 42.6 ± 36, p = 0.006) and no significant alterations in the amlodipine group (from 29.6 ± 42.5 to 24.2 ± 27.7, p = NS). In conclusion, treatment with telmisartan results in a significant attenuation of MCP-1 gene expression and an increase of PPAR-γ gene expression in peripheral monocytes in patients with essential hypertension. Our findings may provide new insights into the cardiovascular protection of telmisartan in hypertensives.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Riou S.
        • Mees B.
        • Esposito B.
        • Merval R.
        • Vilar J.
        • Stengel D.
        • Ninio E.
        • van Haperen R.
        • de Crom R.
        • Tedgui A.
        • Lehoux S.
        High pressure promotes monocyte adhesion to the vascular wall.
        Circ Res. 2007; 100: 1226-1233
        • Hilgers K.F.
        Monocytes/macrophages in hypertension.
        J Hypertens. 2002; 20: 593-596
        • Moraes L.A.
        • Piqueras L.
        • Bishop-Bailey D.
        Peroxisome proliferator-activated receptors and inflammation.
        Pharmacol Ther. 2006; 110: 371-385
        • Mancia G.
        • de Backer G.
        • Dominiczak A.
        • Cifkova R.
        • Fagard R.
        • Germano G.
        • Grassi G.
        • Heagerty A.M.
        • Kjeldsen S.E.
        • Laurent S.
        • Narkiewicz K.
        • Ruilope L.
        • Rynkiewicz A.
        • Schmieder R.E.
        • Boudier H.A.
        • Zanchetti A.
        Guidelines for the Management of Arterial Hypertension.
        J Hypertens. 2007; 25: 1751-1762
        • Schupp M.
        • Janke J.
        • Clasen J.
        • Unger T.
        • Kintscher U.
        Angiotensin type 1 receptor blockers induce peroxisome proliferator activated receptor-gamma activity.
        Circulation. 2004; 109: 2054-2057
        • Zapolska-Donar D.
        • Siennicka A.
        • Chełstowski K.
        • Widecka K.
        • Goracy I.
        • Hałasa M.
        • Mashalinski B.
        • Naruszewicz M.
        Is there an association between angiotensin-converting enzyme gene polymorphism and functional activation of monocytes and macrophage in young patients with essential hypertension?.
        J Hypertens. 2006; 24: 1565-1573
        • Gu L.
        • Tseng S.C.
        • Rollins B.J.
        Monocyte chemoattractant protein-1.
        Chem Immunol. 1999; 72: 7-29
        • Tucci M.
        • Quatraro C.
        • Frassanito M.A.
        • Silvestris F.
        Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia.
        J Hypertens. 2006; 24: 1307-1318
        • Usui M.
        • Egashira K.
        • Tomita H.
        • Koyanagi M.
        • Katoh M.
        • Shimokawa H.
        • Takeya M.
        • Yoshimura T.
        • Matsushima K.
        • Takeshita A.
        Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats.
        Circulation. 2000; 101: 305-310
        • Koh K.K.
        • Ahn J.Y.
        • Han S.H.
        • Kim D.S.
        • Jin D.K.
        • Kim H.S.
        • Shin M.S.
        • Ahn T.H.
        • Choi I.S.
        • Shin E.K.
        Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
        J Am Coll Cardiol. 2003; 42: 905-910
        • Jiang Y.
        • Beller D.I.
        • Frendl G.
        • Graves D.T.
        Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes.
        J Immunol. 1992; 148: 2423-2428
        • Hernandez-Presa M.
        • Bustos C.
        • Ortego M.
        • Tunon J.
        • Renedo G.
        • Ruiz Ortega M.
        • Egido J.
        Angiotensin-converting enzyme inhibition prevent arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis.
        Circulation. 1997; 95: 1532-1541
        • Ishibashi M.
        • Hiasa K.
        • Zhao Q.
        • Inoue S.
        • Ohtani K.
        • Kitamoto S.
        • Tsuchihashi M.
        • Sugaya T.
        • Charo I.F.
        • Kura S.
        • Tsuzuki T.
        • Ishibashi T.
        • Takeshita A.
        • Egashira K.
        Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling.
        Circ Res. 2004; 14: 1203-1210
        • Ni W.
        • Kitamoto S.
        • Ishibashi M.
        • Usui M.
        • Inoue S.
        • Hiasa K.
        • Zhao Q.
        • Nishida K.
        • Takeshita A.
        • Egashira K.
        Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice.
        Arterioscler Thromb Vasc Biol. 2004; 24: 534-539
        • Dai Q.
        • Xu M.
        • Yao M.
        • Sun B.
        Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats.
        Br J Pharmacol. 2007; 152: 1042-1048
        • Fliser D.
        • Buchholz K.
        • Haller H.
        Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
        Circulation. 2004; 110: 1103-1107
        • Chen F.L.
        • Yang Z.H.
        • Liu Y.
        • Li L.X.
        • Liang W.C.
        • Wang X.C.
        • Zhou W.B.
        • Yang Y.H.
        • Hu R.M.
        Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway.
        Endocrine. 2008; 33: 331-337
        • Ishibashi M.
        • Egashira K.
        • Hiasa K.
        • Inoue S.
        • Ni W.
        • Zhao Q.
        • Usui M.
        • Kitamoto S.
        • Ichiki T.
        • Takeshita A.
        Antiinflammatory and antiarteriosclerotic effects of pioglitazone.
        Hypertension. 2002; 40: 687-693
        • Cianchetti S.
        • Del Fiorentino A.
        • Colognato R.
        • Di Stefano R.
        • Franzoni F.
        • Pedrinelli R.
        Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells.
        Atherosclerosis. 2008; 198: 22-28
        • Kaschina E.
        • Schrader F.
        • Sommerfeld M.
        • Kemnitz U.R.
        • Grzesiak A.
        • Krikov M.
        • Unger T.
        Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation.
        J Hypertens. 2008; 26 (2631–2373)
        • Nakamura T.
        • Inoue T.
        • Suzuki T.
        • Kawagoe Y.
        • Ueda Y.
        • Koide H.
        • Node K.
        Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency.
        Hypertens Res. 2008; 31: 841-850
        • Kappert K.
        • Tsuprykov O.
        • Kaufmann J.
        • Fritzsche J.
        • Ott I.
        • Goebel M.
        • Bahr I.N.
        • Haβle P.L.
        • Gust R.
        • Fleck E.
        • Unger T.
        • Stawowy P.
        • Kintscher U.
        Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARγ activation.
        Hypertension. 2009; 54: 738-743
        • Ikejima H.
        • Imanishi T.
        • Tsujioka H.
        • Kuroi A.
        • Kobayashi K.
        • Shiomi M.
        • Muragaki Y.
        • Mochizuki S.
        • Goto M.
        • Yoshida K.
        • Akasaka T.
        Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
        J Hypertens. 2008; 26: 964-972
        • Pelliccia F.
        • Pasceri V.
        • Cianfrocca C.
        • Vitale C.
        • Speciale G.
        • Gaudio C.
        • Rosano G.M.
        • Mercuro G.
        Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study.
        Atherosclerosis. 2010; 210: 510-515
        • Ishii N.
        • Matsumura T.
        • Kinoshita H.
        • Fukuda K.
        • Motoshima H.
        • Senokuchi T.
        • Nakao S.
        • Tsutsumi A.
        • Kim-Mitsuyama S.
        • Kawada T.
        • Takeya M.
        • Miyamura N.
        • Nishikawa T.
        • Araki E.
        Nifedipine induces peroxisome proliferator-activated receptor-gamma activation in macrophages and suppresses the progression of atherosclerosis in apolipoprotein E-deficient mice.
        Arterioscler Thromb Vasc Biol. 2010; 30: 1598-1605
        • Martin-Ventura J.L.
        • Muñoz-Garcia B.
        • Blanco-Colio L.M.
        • Martín-Conejero A.
        • Madrigal-Matute J.
        • Vega M.
        • Ortega L.
        • Serrano J.
        • Egido J.
        Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis.
        Kidney Int Suppl. 2008; 111: S71-S74
        • Ricote M.
        • Huang J.
        • Fajas L.
        • Li A.
        • Welch J.
        • Najib J.
        • Witztum J.L.
        • Auwerx J.
        • Palinski W.
        • Glass C.K.
        Expression of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein.
        Proc Natl Acad Sci U S A. 1998; 95: 7614-7619
        • Xin X.
        • Yang S.
        • Kowalski J.
        • Gerritsen M.E.
        Peroxisome proliferator-activated receptor-gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo.
        J Biol Chem. 1999; 274: 9116-9121
        • Law R.E.
        • Goetze S.
        • Xi X.P.
        • Jackson S.
        • Kawano Y.
        • Demer L.
        • Fishbein M.C.
        • Meehan W.P.
        • Hsueh W.A.
        Expression and function of PPAR-gamma in rat and human vascular smooth muscle cells.
        Circulation. 2000; 101: 1311-1318
        • Kintscher U.
        • Wakino S.
        • Bruemmer D.
        • Goetze S.
        • Graf K.
        • Hsueh W.A.
        • Law R.E.
        TGF-beta(1) induces peroxisome proliferator-activated receptor gamma1 and gamma2 expression in human THP-1 monocytes.
        Biochem Biophys Res Commun. 2002; 297: 794-799
        • von Knethen A.
        • Brune B.
        PPAR-gamma—an important regulator of monocyte/macrophage function.
        Arch Immunol Ther Exp. 2003; 51: 219-226